You want to keep your trial on track, but physical distancing and travel restrictions have made it difficult. Fortunately, IMARC has experience providing remote services.
As the cell therapy market continues to grow, it’s important to note the similarities between medical device and cell therapy clinical trials. To help illustrate this, we’ve created an infographic, “Cell Therapy: The Fourth Pillar of Healthcare,” which is available for download.
Topics: Cell Therapy, Chris Mason, FDA
As the cell therapy market continues to grow, it’s important to note the similarities between medical device and cell therapy clinical trials. To help illustrate this, we’ve created an infographic, “Cell Therapy: The Fourth Pillar of Healthcare,” which is available for download.
Topics: Infographic, Cell Therapy, Chris Mason, FDA
In the current issue of ACRP's The Monitor, there is an interesting article regarding a different approach for monitoring federally-funded studies. In an effort to reduce cost and increase efficiency in regards to monitoring federally-funded studies, groups such as the Cardiovascular Cell Therapy Research Network (CCTRN) have been created. The CCTRN was established by the National Heart, Lung, and Blood Institute (NHLBI) with the goals to “develop, coordinate, and simultaneously conduct multiple collaborate trials testing the effects of cell therapy in cardiovascular disease”. The article states that there was a particular goal to assist in investigator-initiated studies.
Topics: Cell Therapy, Cardiovascular Cell Therapy Research Network, ACRP
As the cell therapy market continues to grow, it’s important to note the similarities between medical device and cell therapy clinical trials. To help illustrate this, we’ve created an infographic, “Cell Therapy: The Fourth Pillar of Healthcare,” which is available for download.
Topics: Infographic, Cell Therapy, Fourth Pillar, IMARC Research
Not too long ago we posted a blog on cell therapy trials. This is an emerging field in clinical research and one we are very excited about. While the FDA is still in the process of building a foundation of the cell therapy industry, there exists a need for this type of medical development to meet the needs of patients. Before any of these life-saving innovations can reach the public, they must meet the requirements for being proven safe and effective in clinical research- and have success in clinical trials. Looks like FDA is taking steps in this direction.
Topics: FDA Guidance, Cell Therapy, Gene Therapy, Clinical Research